AzTrials
AzTrials

Myocardial IschemiaFUSE-HEARTNCT04680689

Assessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging

An observational study of Myocardial Ischemia and Myocardial Viability, run by Cardio Med Medical Center at 1 site in Romania.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the Fused-Heart study is to investigate the impact of a coronary artery stenosis on myocardial function and viability, based on advanced fusion imaging techniques derived from CCTA. Read more about this study

Who is it for?
Ages 18 to 90 years
What is being tested?
128 Multislice CT coronary angiography, 2D Cardiac Transthoracic Echocardiography and Laboratory Blood tests
How many people
100 participants
Where
1 siteRomania
Study dates
30 Jul 2021to 1 Jan 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study will include 100 subjects with coronary lesions depicted by CCTA examination. The study population will consist in: (1) patients with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries, or (2) patients surviving an acute myocardial infarction, revascularized or not.

Who may be able to join

  • Patients undergoing CCTA examination, with at least one coronary artery lesion producing a luminal narrowing >50%
  • Ability to provide informed consent;
  • Patients aged at least 18 years;

Who cannot join

  • Unwillingness or incapacity to provide informed consent;
  • Allergy to contrast media;
  • Absolute or relative contraindications to CCTA imaging;
  • Irregular or rapid heart rhythm
  • Pregnancy or lactation;
  • Women with childbearing potential in absence of any contraceptive treatment;
Show all 9Show fewer
  • Renal insufficiency (creatinine greater than 1.5 mg/dL) or renal failure requiring dialysis;
  • Active malignancy or malignancy within the last 5 year prior to enrollment;
  • Conditions associated with an estimated life expectancy of under 2 years;

Trial locations and contacts

1 site in 1 country.

Romania1 site
  • Cardio Med Medical Center

    Târgu Mureş, Mureș County, 540102

Other trials in Romania

About this study

Official title: Assessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging- the FUSE-HEART Study: Protocol for a Non-randomised Clinical Trial

The aim of the Fused-Heart study is to investigate the impact of a coronary artery stenosis on myocardial function and viability, based on advanced fusion imaging techniques derived from CCTA.

Moreover the study will investigate the correlation between morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery.

Read the detailed description

The FUSE-HEART study is a prospective, observational, single-center, cohort study that will be conducted in the Laboratory of Advanced Research in Cardiac Multimodal Imaging of Cardio Med Medical Center Targu Mures, Romania.

The study will include 100 subjects with coronary lesions depicted by CCTA examination. The study population will consist in: (1) patients with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries, or (2) patients surviving an acute myocardial infarction, revascularized or not. In all patients, presence of vulnerability features in the atheromatous plaques will be studied and the vulnerability score will be calculated for each plaque, consisting in one point added for each of the following vulnerability markers: positive remodeling, napkin-rink sign, presence of low density plaque or spotty calcium within the plaque. In addition, following 3D fusion of the images of the coronary tree with the images reflecting wall motion, the correspondence between plaque morphology and composition on one hand, and wall motion in the corresponding distribution territory of that coronary artery, will be studied based on fused models.

The study will be conducted over a period of 2 years, in which patients will be examined at baseline, with a projected recruitment period of 1 year and will be followed-up 1 year for MACE.

Study objectives:

Primary: to investigate the impact of a coronary artery stenosis on myocardial function and viability, based on advanced fusion imaging techniques derived from CCTA.

Secondary: to investigate the correlation between morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery.

Study timeline:

  • Baseline (day 0)-Obtain and document consent from participant on study consent form.

Verify inclusion/exclusion criteria. Obtain demographic information, medical history, medication history, alcohol and tobacco use history. Record results of physical examinations and 12-lead ECG.Collect blood specimens (complete blood count, biochemistry and inflammatory biomarkers).Imaging procedures: CCTA-Image processing - quantification of coronary stenosis, characterization of vulnerability markers, 3D reconstruction, extension and characterization of wall motion. Deliver fused 3D images

  • Visit 1 (month 1)-Record results of physical examinations, 12-lead ECG, blood pressure, and medical history. MACE assessment Visit 2 (month 3) -Telephone visit with target questions, all the answers recorded in study forms Visit 3 (month 6) - Record results of physical examinations, 12-lead ECG, blood pressure, and medical history. MACE assessment

Final study visit (month 12)- Record results of physical examinations, medical history,12-lead ECG, blood pressure, transthoracic 2-D echocardiography. End-point and MACE evaluation.

Study procedures:

  • Medical history, clinical examination, laboratory tests (complete blood count, biochemistry, inflammatory biomarkers: hs-CRP, MMP, IL6 and NT-pro-BNP);
  • 12-lead ECG
  • 2D transthoracic echocardiography
  • CCTA
  • Computerized postprocessing and fused images

Data collection:

All the information will be collected in a dedicated database including medical history, medication, imaging features provided by cardiac ultrasound, CCTA and fused images resulting from imaging post-processing.

Being tested
128 Multislice CT coronary angiography, 2D Cardiac Transthoracic Echocardiography, Laboratory Blood tests
Keywords
Fusion imaging, CCTA, Myocardial viability, Vulnerable coronary plaques
Medical subject headings
Myocardial Ischemia, Coronary Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 128 Multislice CT coronary angiographyDiagnostic test

    Also called CCTA

    128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium

  • 2D Cardiac Transthoracic EchocardiographyDiagnostic test

    2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions

  • Laboratory Blood testsDiagnostic test

    Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry

Study groups in NCT04680689
Study groupRoleWhat they receive
Fuse-Heart -SG 01Study subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries.
Receives: Diagnostic Test: 128 Multislice CT coronary angiography; Diagnostic Test: 2D Cardiac Transthoracic Echocardiography; Diagnostic Test: Laboratory Blood tests
Fuse-Heart -SG 02Study subjects surviving an acute myocardial infarction, revascularized or not.
Receives: Diagnostic Test: 128 Multislice CT coronary angiography; Diagnostic Test: 2D Cardiac Transthoracic Echocardiography; Diagnostic Test: Laboratory Blood tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MACE rate-Major Adverse Cardiovascular Events

    The primary outcome of the study is represented by the rate of MACE events related to myocardial ischemia at 1-year post assessment, in correlation with the degree of coronary artery stenosis and myocardial ischemia or viability.

    Measured: 12 months

Secondary outcomes (2)
  1. Re-hospitalisation rate,

    Secondary outcome refers to rate of re-hospitalization, in correlation with the morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery

    Measured: 12 months

  2. Rate of survival

    This outcome refers to rate of survival in correlation with the morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Dec 2020
  2. Study start30 Jul 2021
  3. Primary completion1 Dec 2022
  4. Study completion1 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04680689
Sponsor's protocol ID
CM0520-FUSEH
Acronym
FUSE-HEART
Status last verified
Feb 2022
First submitted
14 Dec 2020
Last updated
14 Feb 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD that underlie results in a publication will be available for interested parties

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Ischemia and Myocardial Viability, run by Cardio Med Medical Center at 1 site in Romania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MACE rate-Major Adverse Cardiovascular Events (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in